(VIANEWS) – New Mountain Finance Corporation (NMFC), Epsilon Energy Ltd. (EPSN), Bristol (BMY) are the highest payout ratio stocks on this list.
We have gathered information concerning stocks with the highest payout ratio as yet. The payout ratio in itself isn’t a promise of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. New Mountain Finance Corporation (NMFC)
130% Payout Ratio
New Mountain Finance Corporation (Nasdaq: NMFC), a business development company is a private equity / buyouts and loan fund specializes in directly investing and lending to middle market companies in “defensive growth” industries. The fund prefers investing in buyout and middle market companies. It also makes investments in debt securities at all levels of the capital structure including first and second lien debt, unsecured notes, and mezzanine securities. In some cases, its investments may also include equity interests. It targets energy, engineering and consulting services, specialty chemicals and materials, trading companies and distributors, commercial printing, diversified support services, education services, environmental and facilities services, office services and supplies, media, distributors, health care services, health care facilities, application software, business services, systems software, federal services, distribution and logistics, interactive home entertainment, telecommunication services, hydroelectric power generation, electric power generation by fossil fuels, electric power generation by nuclear fuels, health care technology, and security and alarm services. The fund seeks to invest in United States of America. It seeks to invest between $10 million and $125 million per transaction. The firm invests through both primary originations and open-market secondary purchases. It invests in companies with EBITDA between $10 million and $200 million. The fund seeks a majority stake in its portfolio companies.
Earnings Per Share
As for profitability, New Mountain Finance Corporation has a trailing twelve months EPS of $1.1.
PE Ratio
New Mountain Finance Corporation has a trailing twelve months price to earnings ratio of 11.47. Meaning, the purchaser of the share is investing $11.47 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.82%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 14, 2024, the estimated forward annual dividend rate is 1.36 and the estimated forward annual dividend yield is 10.78%.
2. Epsilon Energy Ltd. (EPSN)
80.65% Payout Ratio
Epsilon Energy Ltd., a natural gas and oil company, engages in the acquisition, development, gathering, and production of oil and gas reserves in the United States. It operates through Upstream and Gathering System segments. The company primarily focuses on the Marcellus Shale comprising 3,979 net acres located in the Susquehanna County, Pennsylvania; and Anadarko basin comprising 8,594 net acres located in the Oklahoma. As of December 31, 2020, it had total estimated net proved reserves of 88,658 million cubic feet of natural gas reserves and 371,343 barrels of oil and other liquids. Epsilon Energy Ltd. was incorporated in 2005 and is based in Houston, Texas.
Earnings Per Share
As for profitability, Epsilon Energy Ltd. has a trailing twelve months EPS of $0.31.
PE Ratio
Epsilon Energy Ltd. has a trailing twelve months price to earnings ratio of 17.55. Meaning, the purchaser of the share is investing $17.55 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.78%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Mar 14, 2024, the estimated forward annual dividend rate is 0.25 and the estimated forward annual dividend yield is 4.6%.
Yearly Top and Bottom Value
Epsilon Energy Ltd.’s stock is valued at $5.44 at 20:23 EST, way under its 52-week high of $6.35 and way higher than its 52-week low of $4.70.
Volume
Today’s last reported volume for Epsilon Energy Ltd. is 12854 which is 63.79% below its average volume of 35508.
Revenue Growth
Year-on-year quarterly revenue growth declined by 43.7%, now sitting on 30.73M for the twelve trailing months.
3. Bristol (BMY)
59.84% Payout Ratio
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Earnings Per Share
As for profitability, Bristol has a trailing twelve months EPS of $3.86.
PE Ratio
Bristol has a trailing twelve months price to earnings ratio of 12.51. Meaning, the purchaser of the share is investing $12.51 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -25.33%.
Volume
Today’s last reported volume for Bristol is 10036300 which is 37.75% below its average volume of 16123300.
Revenue Growth
Year-on-year quarterly revenue growth grew by 4.7%, now sitting on 45.53B for the twelve trailing months.
Yearly Top and Bottom Value
Bristol’s stock is valued at $48.28 at 20:23 EST, way under its 52-week high of $69.10 and way higher than its 52-week low of $43.33.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 3.4% and a negative 9.3%, respectively.
Previous days news about Bristol (BMY)
- The zacks analyst blog highlights Novavax, sanofi, fulcrum therapeutics, Moderna and bristol myers. According to Zacks on Friday, 17 May, "Stocks recently featured in the blog include: Novavax, Inc. (NVAX Quick QuoteNVAX – Free Report) , Sanofi (SNY Quick QuoteSNY – Free Report) , Fulcrum Therapeutics, Inc. (FULC Quick QuoteFULC – Free Report) , Moderna, Inc. (MRNA Quick QuoteMRNA – Free Report) and Bristol Myers (BMY Quick QuoteBMY – Free Report) .", "Updates from BMY: Bristol Myers announced that the FDA had granted accelerated approval to the label expansion of chimeric antigen receptor (CAR) T cell therapy Breyanzi (lisocabtagene maraleucel; liso-cel). "
- According to Zacks on Friday, 17 May, "We have been flagging an acceleration in the earnings growth trend, which becomes more clear once the Bristol Myers drag is removed from the data; the pharma giant came out with a huge one-time charge. "
4. Great Elm Capital Corp. (GECC)
42.04% Payout Ratio
Great Elm Capital Corporation is a business development company which specializes in loan and mezzanine, middle market investments. The fund prefers to invest in media, commercial services and supplies, healthcare, telecommunication services, communications equipment. It typically makes equity investments between $3 million and $10 million in companies with revenues between $3 million and $75 million.
Earnings Per Share
As for profitability, Great Elm Capital Corp. has a trailing twelve months EPS of $3.33.
PE Ratio
Great Elm Capital Corp. has a trailing twelve months price to earnings ratio of 3.07. Meaning, the purchaser of the share is investing $3.07 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.6%.
Yearly Top and Bottom Value
Great Elm Capital Corp.’s stock is valued at $10.21 at 20:23 EST, way below its 52-week high of $11.82 and way higher than its 52-week low of $7.51.
Revenue Growth
Year-on-year quarterly revenue growth grew by 25.1%, now sitting on 35.83M for the twelve trailing months.
5. Kinross Gold (KGC)
33.33% Payout Ratio
Kinross Gold Corporation, together with its subsidiaries, engages in the acquisition, exploration, and development of gold properties principally in the United States, Brazil, Chile, Canada, and Mauritania. The company operates the Fort Knox mine and the Manh Choh project in Alaska, as well as the Round Mountain and the Bald Mountain mines in Nevada, the United States; the Paracatu mine in Brazil; the La Coipa and the Lobo-Marte project in Chile; the Tasiast mine in Mauritania; and the Great Bear project in Canada. It is also involved in the extraction and processing of gold-containing ores; reclamation of gold mining properties; and production and sale of silver. Kinross Gold Corporation was founded in 1993 and is headquartered in Toronto, Canada.
Earnings Per Share
As for profitability, Kinross Gold has a trailing twelve months EPS of $0.34.
PE Ratio
Kinross Gold has a trailing twelve months price to earnings ratio of 18.75. Meaning, the purchaser of the share is investing $18.75 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.06%.
Sales Growth
Kinross Gold’s sales growth is 2% for the present quarter and 16% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 16.4%, now sitting on 4.39B for the twelve trailing months.
Previous days news about Kinross Gold (KGC)
- According to Zacks on Friday, 17 May, "On May 7, Kinross Gold reported adjusted earnings of 10 cents per share in the first quarter. "
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of $1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing $1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
1’s EBITDA is 1.
Volatility
1’s last week, last month’s, and last quarter’s current intraday variation average was 1.00%, 1.00%, and 1.00%.
1’s highest amplitude of average volatility was 1.00% (last week), 1.00% (last month), and 1.00% (last quarter).
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 1% and 1%, respectively.
